Rostra Therapeutics is a new company that will be spun-out from the University of Strathclyde. Its mission is to develop a novel platform of molecules, the 2nd generation Strathclyde Minor Groove Binders (S-MGBs), into medicines to address unmet clinical need.  Various S-MGBs have demonstrated efficacy against many different pathogens including fungi, viruses, bacteria and parasites. Rostra Therapeutics will create and capture value by discovering, patent protecting and developing novel molecules into medicines to treat a variety of serious infectious diseases, with the potential to expand into other therapy areas such as oncology.

 

Approximately 15M people die each year from infectious diseases. This ever-present threat to global health and well-being, and economic prosperity necessitates new and effective therapeutic options to improve the health of patients globally. Rostra Therpeutics has been founded to achieve this goal through its vision to ‘Restore health and save lives through innovative medicines’.

​

Focus on Serious Fungal Disease

​

The initial focus of Rostra Therapeutics will be on developing specific S-MGBs for the treatment of serious and invasive fungal infections.  This represents an area of significant unmet clinical need with over 1.5 million deaths from fungal disease each year globally.